Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London

Source Summary

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical company developing investigational therapies and diagnostic assays for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present nine posters on its lead investigational therapy, valiltramiprosate/ALZ-801, at the 2026 Alzheimer’s Association International Conference (AAIC) in London, United Kingdom. The presentations will feature expanded analyses from the Phase 3 APO